Arndt Vogel, MD

Articles

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

June 24th 2024

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

June 2nd 2024

Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

The Future of Liver Function Assessments in HCC

October 31st 2023

Experts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.

Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310

October 25th 2023

Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.

Key Outcomes Data in Patients With HCC Based on Liver Function

October 25th 2023

Amit Singal, MD, reviews analyses of the HIMALAYA and KEYNOTE-240 trials, focusing on the impact of liver function via ALBI grades on treatment outcomes and safety in patients with hepatocellular carcinoma.

Updates in First-Line Systemic Therapy for Patients With HCC

October 17th 2023

Arndt Vogel, MD, discusses the post-hoc analyses of two key clinical trials focusing on the impact of liver function, measured by ALBI and Child-Pugh scores, on outcomes in hepatocellular carcinoma treatments.

Assessing Liver Function in Patients With HCC: The MELD Score

October 17th 2023

Rachna Shroff, MD, MS, FASCO, and Amit Singal, MD, discuss the use of various liver function assessment scores—Child-Pugh, ALBI, and MELD—in the care of patients with hepatocellular carcinoma, emphasizing their pros, cons, and roles in treatment decision-making.

Assessing Liver Function in Patients With HCC: The Child-Pugh Score

October 10th 2023

Arndt Vogel, MD, explains that the Child-Pugh score, although simpler to calculate than the ALBI score, sometimes lacks granularity in assessing liver function in hepatocellular carcinoma patients; however, both scoring systems are considered valuable tools in clinical settings and trials for evaluating liver function's prognostic impact on treatment outcomes.

Assessing Liver Function in Patients With HCC: The ALBI Score

October 10th 2023

The ALBI score, originally developed to stratify cirrhotic patients undergoing resection, has evolved into a vital tool for assessing prognosis and treatment efficacy in various stages of hepatocellular carcinoma and is now being explored for its utility in other liver-related diseases.

Importance of Assessing Liver Function in HCC

October 3rd 2023

Drs Vogel and Singal discuss the critical importance of assessing liver function in hepatocellular carcinoma patients, as it impacts prognosis and treatment strategies; they mention the evolution from Child-Pugh scoring to the ALBI score, which uses albumin and bilirubin levels, for a more objective evaluation of liver health.

Risk Factors of Hepatocellular Carcinoma (HCC)

October 3rd 2023

Rachna Shroff, MD, MS, FASCO, discusses hepatocellular carcinoma, noting its rising global incidence and identifying underlying liver cirrhosis as a key risk factor influenced by conditions like viral hepatitis and fatty liver disease; diagnosis often involves radiographic imaging and triple-phase CT and MRI scans, while treatment necessitates a multidisciplinary approach involving hepatologists, surgeons, and other specialists.

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

April 10th 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Management of Child-Pugh B Patients with Advanced HCC

April 3rd 2023

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Treatment Considerations for Advanced HCC in Second Line and Beyond

April 3rd 2023

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

March 27th 2023

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

March 27th 2023

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

March 20th 2023

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

March 20th 2023

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Real-World Evidence for Lenvatinib in Advanced HCC

March 13th 2023

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

Patient Profile 2: Advanced HCC Treated with Lenvatinib

March 13th 2023

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.